Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

Cartography Biosciences raised $67 million in a Series B financing round led by Pfizer Ventures, with participation from Amgen Ventures, LG Corp, Andreessen Horowitz (A16z) Bio + Health, and others1234.

The funding will advance Cartography’s lead therapeutic program, CBI-1214, a T-cell engager for colorectal cancer (CRC), into Phase 1 clinical trials targeted for enrollment in early 2026234.

Cartography is focused on developing antibody-based therapies targeting novel tumor antigens, leveraging large datasets and machine learning through its ATLAS and SUMMIT drug discovery platforms1234.

Michael Baran, Partner at Pfizer Ventures, will join Cartography's Board of Directors as part of this deal134.

The investment will also help accelerate the advancement of additional oncology programs beyond CBI-1214, further expanding Cartography’s pipeline34.

Sources:

1. https://www.fundz.net/fundings/cartography-funding-round-series-b-c8d7d7

2. https://www.fundz.net/fundings/cartography-biosciences-funding-round-series-b-3b0855

3. https://vcnewsdaily.com/cartography-biosciences/venture-capital-funding/pnfvkmdnbv

4. https://www.businesswire.com/news/home/20251002482177/en/Cartography-Secures-$67-Million-Series-B-Financing-to-Advance-Differentiated-Oncology-Pipeline-of-Antibody-Based-Therapies-into-the-Clinic